Rabies - Pipeline Review, H1 2015

Published: Apr, 2015 | Pages: 80 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Rabies - Pipeline Review, H1 2015

Summary 

Global Markets Direct's, 'Rabies - Pipeline Review, H1 2015', provides an overview of the Rabies's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rabies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rabies and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rabies
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Rabies and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Rabies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Rabies pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason To Buy 

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Rabies
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Rabies pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Rabies Overview 9
Therapeutics Development 10
Pipeline Products for Rabies - Overview 10
Pipeline Products for Rabies - Comparative Analysis 11
Rabies - Therapeutics under Development by Companies 12
Rabies - Therapeutics under Investigation by Universities/Institutes 14
Rabies - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Rabies - Products under Development by Companies 18
Rabies - Products under Investigation by Universities/Institutes 20
Rabies - Companies Involved in Therapeutics Development 21
Beijing Minhai Biotechnology Co., Ltd 21
Celltrion, Inc. 22
CureVac GmbH 23
Humabs BioMed SA 24
Kaketsuken K.K. 25
Kamada Ltd. 26
Medicago Inc. 27
Molecular Targeting Technologies, Inc. 28
NanoViricides, Inc. 29
Novavax, Inc. 30
PaxVax 31
Prosetta Antiviral Inc. 32
Sanofi 33
Serum Institute of India Limited 34
Sinovac Biotech Ltd. 35
Trellis Bioscience, Inc. 36
VBI Vaccines Inc. 37
Zydus Cadila Healthcare Limited 38
Rabies - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Combination Products 40
Assessment by Target 41
Assessment by Mechanism of Action 42
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
CTP-19 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
CV-7201 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
CV-8102 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ebola + rabies vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
human rabies vaccine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
KD-357 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Monoclonal Antibodies for Rabies - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Monoclonal Antibodies to Inhibit Glycoprotein for Rabies - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Monoclonal Antibody for Rabies - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
PAV-866 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
RabiCide-I - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
rabies immune globulin (human) - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
rabies vaccine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
rabies vaccine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
rabies vaccine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
rabies vaccine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
rabies vaccine - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
rabies vaccine - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
rabies virus like particle vaccine - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Rabimabs - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
SII RMab - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
SO-57 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
SOJB - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
VerorabVax - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Rabies - Recent Pipeline Updates 73
Rabies - Dormant Projects 75
Rabies - Product Development Milestones 76
Featured News & Press Releases 76
Mar 04, 2014: Kamada Completes Enrollment in U.S. Pivotal Clinical Trial with KamRAB as a Post-Exposure Treatment for Rabies 76
Jul 15, 2008: Kamada Gains Approval of KamRAB in Israel 76
Oct 23, 2007: Kamada Awarded Another Contract To Deliver Its KamRAB Anti-rabies Vaccination To Latin America 77
May 01, 2007: Kamada Obtains FDA Approval to Commence Phase II and III Clinical Trials For Its KamRAB Anti-rabies Passive Immunization Product 77
Sep 18, 2003: Molecular Targeting Technologies, Inc. Forms Partnership With North China Pharmaceutical Company 77
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 79
Disclaimer 80

List of Tables

Number of Products under Development for Rabies, H1 2015 10
Number of Products under Development for Rabies - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2015 20
Rabies - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2015 21
Rabies - Pipeline by Celltrion, Inc., H1 2015 22
Rabies - Pipeline by CureVac GmbH, H1 2015 23
Rabies - Pipeline by Humabs BioMed SA, H1 2015 24
Rabies - Pipeline by Kaketsuken K.K., H1 2015 25
Rabies - Pipeline by Kamada Ltd., H1 2015 26
Rabies - Pipeline by Medicago Inc., H1 2015 27
Rabies - Pipeline by Molecular Targeting Technologies, Inc., H1 2015 28
Rabies - Pipeline by NanoViricides, Inc., H1 2015 29
Rabies - Pipeline by Novavax, Inc., H1 2015 30
Rabies - Pipeline by PaxVax, H1 2015 31
Rabies - Pipeline by Prosetta Antiviral Inc., H1 2015 32
Rabies - Pipeline by Sanofi, H1 2015 33
Rabies - Pipeline by Serum Institute of India Limited, H1 2015 34
Rabies - Pipeline by Sinovac Biotech Ltd., H1 2015 35
Rabies - Pipeline by Trellis Bioscience, Inc., H1 2015 36
Rabies - Pipeline by VBI Vaccines Inc., H1 2015 37
Rabies - Pipeline by Zydus Cadila Healthcare Limited, H1 2015 38
Assessment by Monotherapy Products, H1 2015 39
Assessment by Combination Products, H1 2015 40
Number of Products by Stage and Target, H1 2015 41
Number of Products by Stage and Mechanism of Action, H1 2015 42
Number of Products by Stage and Route of Administration, H1 2015 44
Number of Products by Stage and Molecule Type, H1 2015 46
Rabies Therapeutics - Recent Pipeline Updates, H1 2015 73
Rabies - Dormant Projects, H1 2015 75